Publicly traded life sciences companies continue to be the primary target of the plaintiffs’ bar, facing far more securities class action lawsuits compared to other sectors. What does this mean for your business, and what practical steps can you take to make informed choices? Join Caroline Bullerjahn, Courtney Orazio, and John Barker as they speak to these pressing issues in Goodwin’s webinar, “2022-2023 Key Trends and Updates: Securities Litigation Against Life Sciences Companies,” taking place on Thursday, June 8th from 2:30 – 3:30 PM ET.
Register today!